Experienced in Cytomegalic Inclusion Disease

Jin C. Yang

No 277 Yanta West Road, 
Xi'an, CN 
Experienced in Cytomegalic Inclusion Disease
No 277 Yanta West Road, 
Xi'an, CN 
OverviewLocationsClinical Research

Overview

Jin Yang practices in Xi'an, China. Yang is rated as an Experienced expert by MediFind in the treatment of Cytomegalic Inclusion Disease. Their top areas of expertise are Breast Cancer, Pituitary Tumor, Prolactinoma, Trabeculectomy, and Endoscopy.

Their clinical research consists of co-authoring 722 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Cytomegalic Inclusion Disease.

Locations

No 277 Yanta West Road, Xi'an, 710061, China
Other Locations
No. 99, Ziyang Avenue, Nanchang, 330022, China
No. 826 Xinan Road, Dalian, 116033, China
277 West Yanta Road, Xi'an, 710061, China
277 Yanta West Road, Xi'an, 710061, China
1111 Xianxia Road, Shanghai, 200336, China
No 277 Yenta West Road, Xi'an, 710061, China
104 Hanzhong Road, Nanjing, 210002, China
305 East Zhongshan Road, Nanjing, 210002, China
185 Donghu Road, Wuhan, 430071, China
Jiangdong Road 699#, Yiwu, China
182 Tongguan Road, Lianyungang, 222001, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3

722 Total Publications

PI3K/Akt/mTOR signaling pathway mediates energy metabolic reprogramming and regulates mitochondrial homeostasis in host cells exposed to Toxoplasma gondii.
PI3K/Akt/mTOR signaling pathway mediates energy metabolic reprogramming and regulates mitochondrial homeostasis in host cells exposed to Toxoplasma gondii.
Journal: Microbiology spectrum
Published: December 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yang's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 100 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile